Aneuploidy; BCR-ABL; CD95/FAS; Chromosome instability; DDR1; EF1A2; EGFR; ESPL1; FGF18; Genetic heterogeneity; HYAL1/2; IDH1/2; KIT; L1M domain containing gene 1; L1MD1; LCK; LTF; MAPK; MTOR; NAD(P)H dehydrogenase, quinone 2; NQO2; PDGFRß; PIK3CA; PTEN; RNASET2; STAT1; TGFB3; Targeted therapy; VHL; WNT1; breakpoint cluster region-Abelson tyrosine-protein kinase; cluster of differentiation 95/cell surface death receptor; discoidin domain receptor tyrosine kinase 1; epidermal growth factor receptor tyrosine kinase; eukaryotic translation elongation factor 1 alpha; extra spindle pole bodies homolog 1; fibroblast growth factor 18; hyaluronoglucosaminidase 1/2; isocitrate dehydrogenases 1/2; lactotransferrin; lymphocyte-specific protein tyrosine kinase; mechanistic target of rapamycin serine/threonine kinase; mitogen-activated protein kinase; phosphatase and tensin homolog; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; pletelet derived growth factor receptor beta; ribonuclease T2; signal transducer and activator of transcription 1; transforming growth factor, beta 3; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, tyrosine kinase receptor; von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase; wingless-type MMTV integration site family, member 1